Product Description
Calcium folinate is a tetrahydrofolic acid. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-folinate)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Puerto Rico, Russia, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 69
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Adenocarcinoma|Anal Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Pancreatic Cancer|Peritoneal Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Bile Duct Cancer|Biliary Tract Cancer|Ductal Carcinoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Liver Cancer|Multiple Sclerosis|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STEREOPAC-001 | P2 |
Unknown Status |
Pancreatic Cancer|Adenocarcinoma |
2032-10-01 |
|
| 2023-509814-12-00 | P2 |
Unknown Status |
Colorectal Cancer |
2031-03-31 |
|
| AndroMETa-GEA | P2 |
Recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2030-10-01 |
|
| ACO/ARO/AIO-18.2 | P3 |
Recruiting |
Colorectal Cancer |
2030-08-01 |